Emend

(fosaprepitant dimeglumine)

Phase 3Small molecule

Emend is one of 64 small molecule programs targeting Chemotherapy-induced nausea and vomiting. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Chemotherapy-Induced Nausea and VomitingActive, not recruiting

Nausea and VomitingActive, not recruiting

Chemotherapy-Induced Nausea and VomitingPhase 3

Active, not recruiting

Nausea and VomitingPreclinical

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Nausea and Vomiting

#DrugCompanyPhaseTrials

Emend

SSteriscience Pte

Phase 3

5 2

Aloxi

AAvyxa

Preclinical

27 3

Alfenta

Alnylam Pharmaceuticals

Preclinical

1 4

Ramosetron

Astellas

Preclinical

15 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

7 6

Phenergan

BBassett Healthcare

Preclinical

5 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Haldol

DDePuy Orthopaedics

Preclinical

3 9

Versed

CConrado Roberto Hoffmann Filho

Preclinical

2 10

Oxycontin

PProtega

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nausea and vomiting5 trials

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

Terminated·UUniversity of Washington·Phase 2·NCT00895245·6 enrolled

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT03578081·690 enrolled

Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

Terminated·OOHSU Knight Cancer Institute·Phase 1/2·NCT01031953·34 enrolled

Show 2 more trials

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Completed·PPhilip Philip·N/A·NCT01504711·30 enrolled

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

Terminated·UUniversity of Southern California·Phase 1·NCT01649258·29 enrolled

Vomiting2 trials

Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT01405924·111 enrolled

Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02732015·37 enrolled

Chemotherapy-induced nausea and vomiting2 trials

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01594749·1,015 enrolled

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT04054193·103 enrolled

Radiotherapy1 trial

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Completed·OOdense University Hospital·Phase 3·NCT01074697·246 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 25, 2008

EMEND

NDA NDA022023

Sep 5, 2019

FOSAPREPITANT DIMEGLUMINE

NDA NDA210064

Aug 22, 2023

FOCINVEZ

NDA NDA216686

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for fosaprepitant dimeglumine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — fosaprepitant dimeglumine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for fosaprepitant dimeglumine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA216686). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Emend. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Steriscience Pte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSteriscience Pte

Patent Landscape[5]

Patent Cliff

Jan 11, 2039

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12042504Jan 11, 2039

11065265Jan 11, 2039

Emend

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nausea and vomiting5 trials

Vomiting2 trials

Chemotherapy-induced nausea and vomiting2 trials

Radiotherapy1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News